Close Menu

Drug companies are setting up R&D arms in China, staffing them with local scientists or expat-trained Chinese scientists, to encourage innovative drug research in the country. The GSK R&D center in Shanghai will have a first-year operating budget of $40 million, and AstraZeneca’s Innovation Center China was set up in June 2006 to develop drugs for gastric tract and liver cancers that are prevalent in China.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.

 

University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.